Cannabinoides Concentrations and Hyperemesis Syndrom Occurrence in Regular Cannabis Consumer (CANEMESE)

Poitiers University Hospital

Status: Unknown

Conditions: Chronic Consumption of Cannabis

Treatments: Procedure: 1 blood sample

Study type: Interventional

Funder types: Other

Identifiers

NCT04836611

CANEMESE

Details and patient eligibility

About

The Cannabinoide Hyperemesis Syndrom (CHS) is defined as a recurrent syndrome of intractable vomiting that occurs in chronic cannabis consumers. The diagnosis is linked to clinical criteria only. The physiopathology of CHS is unknown and we observe an increase of cases with this syndrom since 2016 (Schreck et al., 2018).

The aim of this study is to investigate the involvement of exogenous cannabinoids concentrations in chronic cannabis users in the occurrence of CHS.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects without protection by a legal regime (guardianship, trusteeship)
• Subjects affiliated to an appropriate social security system
• Subjects must sign an informed consent form

Inclusion Criteria for Group 1:

• Subjects must have the CHS diagnosis confirmed

Inclusion Criteria for Group 2:

• Subjects must be chronic cannabis consumers and never had CHS

Exclusion criteria

• Subjects must not have addictive comorbidities or psychoactive substance abuse (except alcohol and tabacco)

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

200 participants in 1 patient group

regular cannabis consumer patients

Other group

Treatment:

Procedure: 1 blood sample